Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

Nordic Life Science Insight's Logo
AbbVie to Present at the UBS Global Healthcare Conference
Pharma

AbbVie to Present at the UBS Global Healthcare Conference

AbbVie
May 9, 2018

InDex Pharmaceuticals develops oral formulation of cobitolimod
Pharma

InDex Pharmaceuticals develops oral formulation of cobitolimod

InDex Pharmaceuticals
May 7, 2018

AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology
Pharma

AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology

AbbVie
May 2, 2018

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Pharma

AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

AbbVie
May 2, 2018

AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Pharma

AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

AbbVie
May 2, 2018

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Pharma

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

AbbVie
April 26, 2018

Date
Title
Author
April 26, 2018
AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
AbbVie
April 26, 2018
Annual General Meeting 2018
InDex Pharmaceuticals
April 26, 2018
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
InDex Pharmaceuticals
April 26, 2018
AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference
AbbVie
April 26, 2018
InDex Pharmaceuticals announces the agenda for its Capital Markets Day in Stockholm on April 25, 2018
InDex Pharmaceuticals
April 12, 2018
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
AbbVie
April 9, 2018
AbbVie to Host First-Quarter 2018 Earnings Conference Call
AbbVie
April 5, 2018
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis
AbbVie
April 4, 2018
FDA approves inclusion of data from safety outcomes trial in the Tresiba® label
Novo Nordisk
April 4, 2018
InDex Pharmaceuticals gets new patent in Japan
InDex Pharmaceuticals
April 4, 2018
AbbVie is Now Accepting CF Scholarship Applications from Students with Cystic Fibrosis for 2018-2019 Academic School Year
AbbVie
March 21, 2018
AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma
AbbVie
March 21, 2018
Semaglutide injection phase 2 data presented at ENDO demonstrated significant weight loss in adults with obesity
Novo Nordisk
March 16, 2018
Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis
AbbVie
March 13, 2018
AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
AbbVie
March 8, 2018
Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month
AbbVie
February 28, 2018
Novo Nordisk files for regulatory approval of long-acting factor VIII (N8-GP) in the US and the EU for treatment of hemophilia A
Novo Nordisk
February 27, 2018
AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference
AbbVie
February 27, 2018
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
AbbVie
February 27, 2018
AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases
AbbVie
February 23, 2018
AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
AbbVie
February 23, 2018
AbbVie Increases Dividend and Announces New Stock Repurchase Program
AbbVie
February 22, 2018
InDex Pharmaceuticals presents mechanism of action data for cobitolimod at the ECCO congress
InDex Pharmaceuticals
February 22, 2018
Novo Nordisk Launches Rebinyn® in the United States for People with Hemophilia B
Novo Nordisk
February 21, 2018
Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes
Novo Nordisk
February 21, 2018
Novo Nordisk increased reported operating profit by 1% in 2017 to USD 7.4 billion (5% growth in local currencies)
Novo Nordisk
February 15, 2018
New disposal option for California residents using Novo Nordisk medicines and needles
Novo Nordisk
February 14, 2018
AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis
AbbVie
February 8, 2018
AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
AbbVie
January 16, 2018
AbbVie to Present at the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top
AbbVie
December 13, 2017
AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
AbbVie
December 12, 2017
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
AbbVie
December 12, 2017
IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
AbbVie
December 11, 2017
IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
AbbVie
December 6, 2017
Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes
Novo Nordisk
December 5, 2017
IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint
AbbVie
December 5, 2017
Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
AbbVie
December 1, 2017
InDex Pharmaceuticals reports new mechanism of action data for cobitolimod
InDex Pharmaceuticals
November 27, 2017
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2017
InDex Pharmaceuticals
November 17, 2017
InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee and financial reporting dates for 2018
InDex Pharmaceuticals
November 17, 2017
Together, the Diabetes and Cardiovascular Communities Recognized World Diabetes Day
Novo Nordisk
November 16, 2017
AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
AbbVie
November 15, 2017
Anthony Anderson, Star of ABC's "black-ish," Partners with Novo Nordisk to Launch "Get Real About Diabetes™"
Novo Nordisk
November 10, 2017
"Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support
Novo Nordisk
November 6, 2017
Switching to Tresiba® is Highly Cost-effective and Cost-saving in a Real-world Setting
Novo Nordisk
October 31, 2017
New US study reveals key reasons why millions of people with obesity are not receiving adequate care
Novo Nordisk
October 30, 2017
AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
AbbVie
October 26, 2017
InDex Pharmaceuticals will participate in the United European Gastroenterology Week (UEGW)
InDex Pharmaceuticals
October 26, 2017
Global City Leaders: Cut Obesity By A Quarter To Prevent 100M New Diabetes Cases By 2045
Novo Nordisk
October 24, 2017
AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting
AbbVie
October 24, 2017
Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease
AbbVie
October 23, 2017
Seizing the digital opportunities in pharma
Arthur D. Little AB
October 19, 2017
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide
Novo Nordisk
October 18, 2017
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
AbbVie
October 16, 2017
AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
AbbVie
October 13, 2017
InDex Pharmaceuticals gets new patent in the US
InDex Pharmaceuticals
October 13, 2017
AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology
AbbVie
October 2, 2017
Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin
Novo Nordisk
September 29, 2017
IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes
Novo Nordisk
September 27, 2017
AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan
AbbVie
September 22, 2017
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
AbbVie
September 19, 2017
AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
AbbVie
September 15, 2017
Tresiba® Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death
Novo Nordisk
September 14, 2017
Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes
Novo Nordisk
September 13, 2017
InDex Pharmaceuticals gets new patent granted in Japan
InDex Pharmaceuticals
September 13, 2017
More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Comparator Treatments
Novo Nordisk
September 7, 2017
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
AbbVie
September 6, 2017
Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices
Novo Nordisk
September 5, 2017
Roche Medicine Ready to Fight Breast Cancer
Oslo Cancer Cluster
August 29, 2017
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2017
InDex Pharmaceuticals
August 28, 2017
Victoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events
Novo Nordisk
August 10, 2017
InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US
InDex Pharmaceuticals
July 14, 2017
Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management
Novo Nordisk
July 6, 2017
InDex Pharmaceuticals gets new patent granted in Europe
InDex Pharmaceuticals
July 4, 2017
Results from SWITCH Trials for Tresiba® Published in the Journal of the American Medical Association
Novo Nordisk
June 21, 2017
InDex Pharmaceuticals enrolls first patient in the phase IIb study CONDUCT with cobitolimod
InDex Pharmaceuticals
June 21, 2017
Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes
Spago Nanomedical
June 19, 2017
FDA posts briefing materials prior to Advisory Committee meeting for Victoza® label update
Novo Nordisk
June 12, 2017
Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy
Novo Nordisk
June 7, 2017
FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia
Novo Nordisk
April 28, 2017
The Swedish Drug Discovery & Development Pipeline 2016
SwedenBIO

Featured items

Vessela Kristensen Receives Cancer Research Award
Vessela Kristensen Receives Cancer Research Award
Oslo Cancer Cluster
Strong presence of Nordic skills and innovations in life science at Arab Health 2018
Strong presence of Nordic skills and innovations in life science at Arab Health 2018
Global Pharma Consulting
Introducing Lena Nymo Helli, the new CEO of Abbvie Norway.
Introducing Lena Nymo Helli, the new CEO of Abbvie Norway.
AbbVie
InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US
InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US
InDex Pharmaceuticals

Nordic Life Science - Insight

NLS Insight's goal is to assist the Nordic regions leading innovators in targeting business collaborations, parnership opportunities and investment potential.

info@nlsinsight.com
+47 69 51 02 XX
Olaf Helsets vei 5, 0694 Oslo
Mail iconinfo@nlsinsight.com
Phone Icon+47 69 51 01 94
Adress IconOlaf Helsets vei 5, 0694 Oslo
Facebook icon
Twitter icon
Subscribe to
our newsletters

Designed by Horn Digital Media 2017